Protagenic Therapeutics Asset Resilience Ratio
Protagenic Therapeutics asset resilience ratio. Protagenic Therapeutics (PTIX) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PTIX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Protagenic Therapeutics (2007–2024)
Asset resilience ratio of Protagenic Therapeutics from 2007 to 2024. This chart shows how Protagenic Therapeutics's Asset Resilience Ratio has changed over time. Read total liabilities of Protagenic Therapeutics for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Protagenic Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PTIX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Protagenic Therapeutics maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Protagenic Therapeutics Industry Peers by Asset Resilience Ratio
Compare Protagenic Therapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Protagenic Therapeutics Asset Resilience Ratio by Year (2007–2024)
Protagenic Therapeutics asset resilience ratio by year from 2007 to 2024. The table below shows the annual Asset Resilience Ratio data for Protagenic Therapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $1.96 Million | -- |
| 2023-12-31 | 64.03% | $2.77 Million | $4.32 Million | -32.57pp |
| 2022-12-31 | 96.59% | $7.76 Million | $8.04 Million | +7.71pp |
| 2021-12-31 | 88.88% | $9.83 Million | $11.06 Million | +16.69pp |
| 2017-12-31 | 72.19% | $1.29 Million | $1.78 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $3.16 Million | -- |
| 2008-12-31 | 5.39% | $4.25 Million | $78.76 Million | -6.45pp |
| 2007-12-31 | 11.84% | $2.84 Million | $23.96 Million | -- |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.